---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-002705"
form_type: "8-K"
ticker: "DFTX"
cik: "0001813814"
company_name: "Definium Therapeutics, Inc."
filed_at: "2024-01-08T23:59:59+00:00"
generated_at: "2026-06-07T02:31:19.559003+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# MindMed provides 2024 outlook; GAD Phase 2b showed 7.6-point HAM-A reduction, ADHD trial failed

## Summary
- MM-120 100µg GAD: 7.6 HAM-A reduction vs placebo (p<0.0004, effect size 0.88); 78% response, 50% remission.
- ADHD Phase 2a sub-perceptual dose trial failed primary endpoint; no further development for that regimen.
- End-of-Phase 2 FDA meeting H1 2024; Phase 3 initiation expected H2 2024 for MM-120 in GAD.
- Full 12-week Phase 2b results for MM-120 in GAD expected by Q1 2024 end.
- Phase 1 for MM-402 (R(-)-MDMA) in ASD started Q4 2023; UHB MDMA trial topline data H1 2024.

## SEC filing metadata
- accession: 0000950170-24-002705
- form_type: 8-K
- ticker: DFTX
- cik: 0001813814
- company_name: Definium Therapeutics, Inc.
- filed_at: 2024-01-08T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1813814/000095017024002705/0000950170-24-002705-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1813814/000095017024002705/mnmd-20240108.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-002705
- JSON: https://secwatch.observer/filing/0000950170-24-002705.json
- Plain text: https://secwatch.observer/filing/0000950170-24-002705.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.